APA (7th ed.) Citation

Payne, M., Danson, S., Kumar, S., Patel, P., Shaw, H., Miller, R., . . . Durrant, L. (2023). 1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Payne, Miranda, et al. 1533 A DNA Plasmid Melanoma Cancer Vaccine, SCIB1, Combined with Nivolumab + Ipilimumab in Patients with Advanced Unresectable Melanoma: Efficacy and Safety Results from the Open-label Phase 2 SCOPE Trial. BMJ Publishing Group, 2023.

MLA (9th ed.) Citation

Payne, Miranda, et al. 1533 A DNA Plasmid Melanoma Cancer Vaccine, SCIB1, Combined with Nivolumab + Ipilimumab in Patients with Advanced Unresectable Melanoma: Efficacy and Safety Results from the Open-label Phase 2 SCOPE Trial. BMJ Publishing Group, 2023.